Antineoplastic effect of proliferation signal inhibitors: From biology to clinical application

Journal of Nephrology

Volumn 22, Issue 4, 2009, Pages 457-462

  Bertoni, Elisabetta ^a   Salvadori, Maurizio ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Angiogenesis cancers; Growth factors; MTOR inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SOMATOMEDIN; TUBERIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; SOMATOMEDIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER RISK; CARCINOID; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; GENE OVEREXPRESSION; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NEUROENDOCRINE TUMOR; NUTRIENT UPTAKE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECT; NEOPLASM; ORGAN TRANSPLANTATION; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; ORGAN TRANSPLANTATION; PROTEIN KINASES; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION;

EID: 70249145495     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int. 2006;19:607-620.
2. Guba M, Graeb C, Jauch K-V, Geissler E. Pro-and anticancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77:1777-1782.
3. Sheil AG. Cancer report 1997. In: Disney AP, ed. The 20th annual report of the Australian and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia: Queen Elisabeth Hospital; 1997:13,138.
4. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical transplants 1998. Los Angeles: UCLA Tissue Typing Laboratory; 1998:147.
5. Geissler EK, Schlitt HJ. The relation between immunosuppressive agents and malignancy. Curr Opin Organ Transplant. 2004;9:394-399.
6. Hanahan D, Weinberg RA. Cell. 2000;100:57-70.
7. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant. 2004;18:446-449.
8. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581-589.
9. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;15:1234-1248.
10. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanisms of action and cellular resistance. Cancer Biol Ther. 2003;2:222-232.
11. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-484.
12. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 2002;16:771-780.
13. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell. 2002;13:2276-2288.
14. Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28:573-576.
15. Jaeschke A, Dennis PB, Thomas G. mTOR: a mediator of intracellular homeostasis. Curr Top Microbiol Immunol. 2004;279:283-298.
16. Mellinghoff IK, Sawyers CL. TORward AKTually useful mouse models. Nat Med. 2004;10:579-580.
17. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1 dependent pathways. Nat Med. 2004;10:594-601.
18. Stoeltzing O, McCarty MF, Wey JS, et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst. 2004;96:946-956.
19. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120:749-759.
20. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954-2963.
21. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002;62:5027-5034.
22. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensibility of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98:10314-10319.
23. Powis G, Kirkpatrick L. Hypoxia inducible factor 1alpha as a cancer drug target. Mol Cancer Ther. 2004;3:647-654.
24. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9(Suppl 5):10-17.
25. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol. 2006;291:271-281.
26. A verous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene. 2006;25:6423-6435.
27. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene. 2006;25:6416-6422.
28. F, Dornhoefer N, Giaccia AJ. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 2006;66:1561-1569.
29. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecanrefractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
30. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101-112.
31. Schips L, Zigeuner R, Ratschek M, Rehak P, Rushoff J, Langner C. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol. 2004;122:931-937.
32. Mandal M, Kim S, Younes MN, et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer. 2005;92:1899-1905.
33. Kantarjian H, Sawyers C, Hochaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
34. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
35. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581-589.
36. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med. 2005;352:1317-1323.
37. de Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant. 2007;22(Suppl 1):i23-i26.
38. Gomez-Camarero J, Salcedo M, Rincon D, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation. 2007;84:786-791.
39. Alberu J, Schena FP, Wali R; for the Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. J Am Soc Nephrol. 2006;17:18A.
40. Motzer RJ, Escudier B, Oudard S, et al; for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
41. Höpfner M, Schuppan D, Scherübl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol. 2008;14:2461-2473.